Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Nitrendipine

Targets (8)Enzymes (3)Transporters (1)Biointeractions (13)

Identification

Name

Nitrendipine

Accession Number

DB01054 (APRD00421)

Type

Small Molecule

Groups

Approved, Investigational

Description

A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]

Structure

Similar Structures

Synonyms

1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
BAY e 5009
Bayotensin
Baypress
Bylotensin
Deiten
Nidrel
Nitrendipino
Nitrendipinum

International/Other Brands

Bayotensin / Baypress / Deiten / Nidrel / Nitrepin / Nitrezic

Categories

UNII

9B627AW319

CAS number

39562-70-4

Weight

Average: 360.3612
Monoisotopic: 360.132136382

Chemical Formula

C₁₈H₂₀N₂O₆

InChI Key

PVHUJELLJLJGLN-UHFFFAOYSA-N

InChI

InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3

IUPAC Name

3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

SMILES

CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate hypertension

Pharmacodynamics

Nitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Target	Actions	Organism
AVoltage-dependent L-type calcium channel subunit alpha-1C	inhibitor	Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit beta-2	inhibitor	Human
AVoltage-dependent calcium channel gamma-1 subunit	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit alpha-1D	inhibitor	Human
AVoltage-dependent L-type calcium channel subunit alpha-1S	inhibitor	Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2	inhibitor	Human
UVoltage-dependent T-type calcium channel subunit alpha-1H	inhibitor	Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

> 99%

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Nitrendipine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2-HYDROXY-1,4-NAPHTHOQUINONE	The therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nitrendipine.	Experimental
2-mercaptobenzothiazole	The therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Nitrendipine.	Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitrendipine.	Experimental
Acebutolol	Nitrendipine may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Acemetacin	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Acemetacin.	Approved, Experimental, Investigational
Acepromazine	The risk or severity of hypotension can be increased when Acepromazine is combined with Nitrendipine.	Approved, Vet Approved
Acetyl sulfisoxazole	The metabolism of Nitrendipine can be decreased when combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Nitrendipine.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin.	Approved
Alfuzosin	Alfuzosin may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Aliskiren	Nitrendipine may increase the hypotensive activities of Aliskiren.	Approved, Investigational
Alprenolol	Alprenolol may increase the hypotensive activities of Nitrendipine.	Approved, Withdrawn
Ambrisentan	Nitrendipine may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amifostine	Nitrendipine may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amiloride.	Approved
Amiodarone	The metabolism of Nitrendipine can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The risk or severity of hypotension can be increased when Amitriptyline is combined with Nitrendipine.	Approved
Amlodipine	Amlodipine may increase the hypotensive activities of Nitrendipine.	Approved
Amobarbital	The metabolism of Nitrendipine can be increased when combined with Amobarbital.	Approved, Illicit
Amorolfine	The therapeutic efficacy of Amorolfine can be increased when used in combination with Nitrendipine.	Approved, Investigational
Amoxapine	The risk or severity of hypotension can be increased when Amoxapine is combined with Nitrendipine.	Approved
Amphetamine	Amphetamine may increase the hypotensive activities of Nitrendipine.	Approved, Illicit, Investigational
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amyl Nitrite.	Approved
Anidulafungin	The therapeutic efficacy of Anidulafungin can be increased when used in combination with Nitrendipine.	Approved, Investigational
Apalutamide	The serum concentration of Nitrendipine can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apomorphine	The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Apraclonidine.	Approved
Aprepitant	The serum concentration of Nitrendipine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Arotinolol	The risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Nitrendipine.	Investigational
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitrendipine.	Approved, Investigational
Artemether	The therapeutic efficacy of Artemether can be increased when used in combination with Nitrendipine.	Approved
Asenapine	The risk or severity of hypotension can be increased when Asenapine is combined with Nitrendipine.	Approved
Asunaprevir	The serum concentration of Asunaprevir can be increased when it is combined with Nitrendipine.	Approved, Investigational, Withdrawn
Atazanavir	The metabolism of Nitrendipine can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	Atenolol may increase the hypotensive activities of Nitrendipine.	Approved
Atomoxetine	The metabolism of Nitrendipine can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Atorvastatin.	Approved
Avanafil	Avanafil may increase the antihypertensive activities of Nitrendipine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Azilsartan medoxomil.	Approved, Investigational
Bafilomycin A1	The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Nitrendipine.	Experimental
Barbexaclone	Barbexaclone may increase the hypotensive activities of Nitrendipine.	Experimental
Barbital	The metabolism of Nitrendipine can be increased when combined with Barbital.	Illicit
Barnidipine	Nitrendipine may increase the antihypertensive activities of Barnidipine.	Approved
Benazepril	Benazepril may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Bendroflumethiazide	Bendroflumethiazide may increase the hypotensive activities of Nitrendipine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Nitrendipine.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be increased when used in combination with Nitrendipine.	Approved, Investigational
Bepridil	Nitrendipine may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betaxolol	Betaxolol may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Bethanidine	Bethanidine may increase the hypotensive activities of Nitrendipine.	Approved
Bevantolol	The risk or severity of hypotension can be increased when Bevantolol is combined with Nitrendipine.	Approved
Bietaserpine	Bietaserpine may increase the hypotensive activities of Nitrendipine.	Experimental
Bifonazole	The therapeutic efficacy of Bifonazole can be increased when used in combination with Nitrendipine.	Approved, Investigational
Bimatoprost	Bimatoprost may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Bisoprolol	Bisoprolol may increase the hypotensive activities of Nitrendipine.	Approved
Boceprevir	The metabolism of Nitrendipine can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The metabolism of Nitrendipine can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Nitrendipine can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Nitrendipine.	Approved
BQ-123	Nitrendipine may increase the hypotensive activities of BQ-123.	Investigational
Brefeldin A	The therapeutic efficacy of Brefeldin A can be increased when used in combination with Nitrendipine.	Experimental
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.	Approved, Investigational
Bretylium	Nitrendipine may increase the hypotensive activities of Bretylium.	Approved
Brexpiprazole	The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nitrendipine.	Approved, Investigational
Brimonidine	Brimonidine may increase the antihypertensive activities of Nitrendipine.	Approved
Brofaromine	Brofaromine may increase the hypotensive activities of Nitrendipine.	Experimental
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitrendipine.	Approved, Investigational
Bucindolol	The risk or severity of hypotension can be increased when Bucindolol is combined with Nitrendipine.	Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Bumetanide.	Approved
Bunazosin	The risk or severity of hypotension can be increased when Bunazosin is combined with Nitrendipine.	Investigational
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine.	Approved, Investigational
Bupranolol	Nitrendipine may increase the hypotensive activities of Bupranolol.	Approved
Butenafine	The therapeutic efficacy of Butenafine can be increased when used in combination with Nitrendipine.	Approved
Butoconazole	The therapeutic efficacy of Butoconazole can be increased when used in combination with Nitrendipine.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Nitrendipine.	Approved
Cadralazine	Cadralazine may increase the hypotensive activities of Nitrendipine.	Experimental
Cafedrine	Nitrendipine may increase the hypotensive activities of Cafedrine.	Investigational
Calcium Acetate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate.	Approved, Investigational
Calcium Carbonate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Carbonate.	Approved, Investigational
Calcium Chloride	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride.	Approved
Calcium Citrate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Citrate.	Approved
Calcium glubionate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate.	Approved
Calcium Gluceptate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate.	Approved
Calcium gluconate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate.	Approved, Vet Approved
Calcium lactate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate.	Approved, Investigational, Vet Approved
Calcium lactate gluconate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate gluconate.	Experimental
Calcium levulinate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium levulinate.	Approved, Experimental
Calcium pangamate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium pangamate.	Experimental
Calcium Phosphate	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Phosphate.	Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Canagliflozin.	Approved
Candesartan	Nitrendipine may increase the hypotensive activities of Candesartan.	Experimental
Candesartan cilexetil	Candesartan cilexetil may increase the hypotensive activities of Nitrendipine.	Approved
Candicidin	The therapeutic efficacy of Candicidin can be increased when used in combination with Nitrendipine.	Withdrawn
Candoxatril	Candoxatril may increase the hypotensive activities of Nitrendipine.	Experimental
Capric acid	The therapeutic efficacy of Capric acid can be increased when used in combination with Nitrendipine.	Experimental
Captopril	Nitrendipine may increase the hypotensive activities of Captopril.	Approved
Carbamazepine	The metabolism of Nitrendipine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine.	Approved, Investigational
Caroxazone	Caroxazone may increase the hypotensive activities of Nitrendipine.	Withdrawn
Carteolol	Carteolol may increase the hypotensive activities of Nitrendipine.	Approved
Carvedilol	Nitrendipine may increase the hypotensive activities of Carvedilol.	Approved, Investigational
Casein	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Casein.	Approved
Caspofungin	The therapeutic efficacy of Caspofungin can be increased when used in combination with Nitrendipine.	Approved
Celiprolol	Nitrendipine may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Ceritinib	The serum concentration of Nitrendipine can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine.	Approved, Withdrawn
Cerulenin	The therapeutic efficacy of Cerulenin can be increased when used in combination with Nitrendipine.	Approved
Chlorothiazide	Chlorothiazide may increase the hypotensive activities of Nitrendipine.	Approved, Vet Approved
Chloroxine	The therapeutic efficacy of Chloroxine can be increased when used in combination with Nitrendipine.	Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrendipine.	Approved, Investigational, Vet Approved
Chlorthalidone	Chlorthalidone may increase the hypotensive activities of Nitrendipine.	Approved
Cicletanine	Nitrendipine may increase the hypotensive activities of Cicletanine.	Investigational
Ciclopirox	The therapeutic efficacy of Ciclopirox can be increased when used in combination with Nitrendipine.	Approved, Investigational
Cilazapril	Nitrendipine may increase the hypotensive activities of Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine.	Approved, Investigational
Cimetidine	The serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.	Approved, Investigational
Clarithromycin	The metabolism of Nitrendipine can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Nitrendipine can be decreased when combined with Clemastine.	Approved, Investigational
Clevidipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine.	Approved, Investigational
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine.	Approved, Investigational, Vet Approved
Clonidine	Clonidine may increase the hypotensive activities of Nitrendipine.	Approved
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine.	Approved
Cloranolol	Nitrendipine may increase the hypotensive activities of Cloranolol.	Experimental
Clotrimazole	The metabolism of Nitrendipine can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Nitrendipine.	Approved
Cobicistat	The metabolism of Nitrendipine can be decreased when combined with Cobicistat.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Nitrendipine.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Nitrendipine.	Approved, Investigational
Cordycepin	The therapeutic efficacy of Cordycepin can be increased when used in combination with Nitrendipine.	Investigational
Crizotinib	The metabolism of Nitrendipine can be decreased when combined with Crizotinib.	Approved
Cryptenamine	Cryptenamine may increase the hypotensive activities of Nitrendipine.	Approved
Curcumin	The metabolism of Nitrendipine can be decreased when combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	Nitrendipine may increase the hypotensive activities of Cyclopenthiazide.	Experimental
Cyclosporine	The metabolism of Nitrendipine can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Nitrendipine.	Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine.	Approved
Dabrafenib	The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dapagliflozin	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dapagliflozin.	Approved
Dapiprazole	The risk or severity of hypotension can be increased when Dapiprazole is combined with Nitrendipine.	Approved
Darunavir	The metabolism of Nitrendipine can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.	Approved, Investigational
Debrisoquin	Debrisoquin may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Deferasirox	The serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delapril	Nitrendipine may increase the hypotensive activities of Delapril.	Experimental
Delavirdine	The metabolism of Nitrendipine can be decreased when combined with Delavirdine.	Approved
Deserpidine	Nitrendipine may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dexmedetomidine.	Approved, Vet Approved
Dextroamphetamine	The risk or severity of hypotension can be increased when Dextroamphetamine is combined with Nitrendipine.	Approved, Illicit
Diazoxide	Diazoxide may increase the hypotensive activities of Nitrendipine.	Approved
Dichlorophene	The therapeutic efficacy of Dichlorophene can be increased when used in combination with Nitrendipine.	Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Diclofenamide.	Approved, Investigational
Diethylnorspermine	Nitrendipine may increase the hypotensive activities of Diethylnorspermine.	Investigational
Dihydralazine	Dihydralazine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nitrendipine.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nitrendipine.	Approved, Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nitrendipine.	Experimental
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nitrendipine.	Approved, Investigational
Diltiazem	The metabolism of Nitrendipine can be decreased when combined with Diltiazem.	Approved, Investigational
Dinutuximab	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab.	Approved, Investigational
Dipyridamole	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dipyridamole.	Approved
Dorzolamide	Dorzolamide may increase the hypotensive activities of Nitrendipine.	Approved
Doxazosin	Doxazosin may increase the hypotensive activities of Nitrendipine.	Approved
Doxepin	The risk or severity of hypotension can be increased when Doxepin is combined with Nitrendipine.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine.	Approved, Investigational
Doxycycline	The metabolism of Nitrendipine can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	The metabolism of Nitrendipine can be decreased when combined with Dronedarone.	Approved
Droperidol	The risk or severity of hypotension can be increased when Droperidol is combined with Nitrendipine.	Approved, Vet Approved
Duloxetine	Nitrendipine may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Econazole	The therapeutic efficacy of Econazole can be increased when used in combination with Nitrendipine.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Nitrendipine.	Approved
Efavirenz	The serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The therapeutic efficacy of Efinaconazole can be increased when used in combination with Nitrendipine.	Approved
Efonidipine	Nitrendipine may increase the hypotensive activities of Efonidipine.	Approved, Investigational
Empagliflozin	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Empagliflozin.	Approved
Enalapril	Enalapril may increase the hypotensive activities of Nitrendipine.	Approved, Vet Approved
Enalaprilat	Nitrendipine may increase the hypotensive activities of Enalaprilat.	Approved
Endralazine	Endralazine may increase the hypotensive activities of Nitrendipine.	Experimental
Enzalutamide	The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.	Approved
Epanolol	Nitrendipine may increase the hypotensive activities of Epanolol.	Experimental
Epinephrine	The risk or severity of hypotension can be increased when Epinephrine is combined with Nitrendipine.	Approved, Vet Approved
Eplerenone	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Eplerenone.	Approved
Epoprostenol	Nitrendipine may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	Eprosartan may increase the hypotensive activities of Nitrendipine.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Nitrendipine.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Nitrendipine.	Approved
Erythromycin	The metabolism of Nitrendipine can be decreased when combined with Erythromycin.	Approved, Investigational, Vet Approved
Escitalopram	The risk or severity of hypotension can be increased when Escitalopram is combined with Nitrendipine.	Approved, Investigational
Esmolol	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Esmolol.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Etacrynic acid.	Approved, Investigational
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Nitrendipine.	Approved
Felodipine	Felodipine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Fenoldopam	Fenoldopam may increase the hypotensive activities of Nitrendipine.	Approved
Fenticonazole	The therapeutic efficacy of Fenticonazole can be increased when used in combination with Nitrendipine.	Experimental
Ferulic acid	Nitrendipine may increase the hypotensive activities of Ferulic acid.	Experimental
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine.	Approved, Investigational
Fluconazole	The metabolism of Nitrendipine can be decreased when combined with Fluconazole.	Approved, Investigational
Flucytosine	The therapeutic efficacy of Flucytosine can be increased when used in combination with Nitrendipine.	Approved, Investigational
Flupentixol	The risk or severity of hypotension can be increased when Flupentixol is combined with Nitrendipine.	Approved, Investigational, Withdrawn
Flutrimazole	The therapeutic efficacy of Flutrimazole can be increased when used in combination with Nitrendipine.	Experimental
Fluvastatin	The serum concentration of Fluvastatin can be increased when it is combined with Nitrendipine.	Approved
Fluvoxamine	The metabolism of Nitrendipine can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Nitrendipine can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	Fosinopril may increase the hypotensive activities of Nitrendipine.	Approved
Fosphenytoin	The metabolism of Nitrendipine can be increased when combined with Fosphenytoin.	Approved, Investigational
Fostamatinib	Fostamatinib may increase the antihypertensive activities of Nitrendipine.	Approved, Investigational
Furazolidone	Furazolidone may increase the hypotensive activities of Nitrendipine.	Approved, Investigational, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Glyphosate	The therapeutic efficacy of Glyphosate can be increased when used in combination with Nitrendipine.	Experimental
Griseofulvin	The therapeutic efficacy of Griseofulvin can be increased when used in combination with Nitrendipine.	Approved, Investigational, Vet Approved
Guanabenz	Guanabenz may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Guanadrel	Guanadrel may increase the hypotensive activities of Nitrendipine.	Approved
Guanazodine	Nitrendipine may increase the hypotensive activities of Guanazodine.	Experimental
Guanethidine	Nitrendipine may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	Guanfacine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Guanoclor	Nitrendipine may increase the hypotensive activities of Guanoclor.	Experimental
Guanoxabenz	Nitrendipine may increase the hypotensive activities of Guanoxabenz.	Experimental
Guanoxan	Nitrendipine may increase the hypotensive activities of Guanoxan.	Experimental
Hachimycin	The therapeutic efficacy of Hachimycin can be increased when used in combination with Nitrendipine.	Experimental
Haloprogin	The therapeutic efficacy of Haloprogin can be increased when used in combination with Nitrendipine.	Approved, Withdrawn
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine.	Approved, Vet Approved
Harmaline	Harmaline may increase the hypotensive activities of Nitrendipine.	Experimental
Hexamethonium	Nitrendipine may increase the hypotensive activities of Hexamethonium.	Experimental
Hexetidine	The therapeutic efficacy of Hexetidine can be increased when used in combination with Nitrendipine.	Approved, Investigational
Hexobarbital	The metabolism of Nitrendipine can be increased when combined with Hexobarbital.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Nitrendipine.	Experimental
Hydralazine	Hydralazine may increase the hypotensive activities of Nitrendipine.	Approved
Hydrochlorothiazide	Hydrochlorothiazide may increase the hypotensive activities of Nitrendipine.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Nitrendipine.	Approved
Idelalisib	The metabolism of Nitrendipine can be decreased when combined with Idelalisib.	Approved
Iloperidone	The risk or severity of hypotension can be increased when Iloperidone is combined with Nitrendipine.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Iloprost is combined with Nitrendipine.	Approved, Investigational
Imatinib	The metabolism of Nitrendipine can be decreased when combined with Imatinib.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Nitrendipine.	Approved
Indapamide	Indapamide may increase the hypotensive activities of Nitrendipine.	Approved
Indenolol	Nitrendipine may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Nitrendipine can be decreased when combined with Indinavir.	Approved
Indoramin	Indoramin may increase the hypotensive activities of Nitrendipine.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Nitrendipine.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Nitrendipine.	Withdrawn
Irbesartan	Irbesartan may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Isavuconazole	The serum concentration of Nitrendipine can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Nitrendipine can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Nitrendipine.	Approved
Isoconazole	The therapeutic efficacy of Isoconazole can be increased when used in combination with Nitrendipine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Dinitrate.	Approved, Investigational
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Mononitrate.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The metabolism of Nitrendipine can be decreased when combined with Isradipine.	Approved, Investigational
Itraconazole	The metabolism of Nitrendipine can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor.	Approved
Ketanserin	Ketanserin may increase the hypotensive activities of Nitrendipine.	Investigational
Ketoconazole	The metabolism of Nitrendipine can be decreased when combined with Ketoconazole.	Approved, Investigational
Labetalol	Labetalol may increase the hypotensive activities of Nitrendipine.	Approved
Lacidipine	Nitrendipine may increase the hypotensive activities of Lacidipine.	Approved, Investigational
Latanoprost	Latanoprost may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine.	Approved
Lercanidipine	Lercanidipine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine.	Approved, Investigational
Levodopa	Nitrendipine may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine.	Approved, Investigational
Linsidomine	Nitrendipine may increase the hypotensive activities of Linsidomine.	Experimental
Lisdexamfetamine	The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nitrendipine.	Approved, Investigational
Lisinopril	Lisinopril may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Nitrendipine.	Approved, Investigational
Lofexidine	Nitrendipine may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Lopinavir	The metabolism of Nitrendipine can be decreased when combined with Lopinavir.	Approved
Lorpiprazole	The serum concentration of Nitrendipine can be increased when it is combined with Lorpiprazole.	Approved
Losartan	Losartan may increase the hypotensive activities of Nitrendipine.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Nitrendipine.	Approved, Investigational
Luliconazole	The serum concentration of Nitrendipine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Nitrendipine can be increased when combined with Lumacaftor.	Approved
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nitrendipine.	Illicit, Investigational, Withdrawn
Macitentan	Nitrendipine may increase the hypotensive activities of Macitentan.	Approved
Magnesium hydroxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium salicylate.	Approved
Magnesium sulfate	The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium sulfate.	Approved, Investigational, Vet Approved
Manidipine	Nitrendipine may increase the hypotensive activities of Manidipine.	Approved, Investigational
Mannitol	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Mannitol.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Nitrendipine.	Withdrawn
Mecamylamine	Mecamylamine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Mepartricin	The therapeutic efficacy of Mepartricin can be increased when used in combination with Nitrendipine.	Experimental
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Nitrendipine.	Experimental
Methazolamide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methazolamide.	Approved
Methohexital	The metabolism of Nitrendipine can be increased when combined with Methohexital.	Approved
Methoserpidine	Nitrendipine may increase the hypotensive activities of Methoserpidine.	Experimental
Methotrimeprazine	The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nitrendipine.	Approved, Investigational
Methyclothiazide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide.	Approved
Methyldopa	Methyldopa may increase the hypotensive activities of Nitrendipine.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitrendipine.	Approved
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Nitrendipine.	Approved, Investigational
Methylphenobarbital	The metabolism of Nitrendipine can be increased when combined with Methylphenobarbital.	Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Nitrendipine.	Approved
Metipranolol	Nitrendipine may increase the hypotensive activities of Metipranolol.	Approved
Metolazone	Metolazone may increase the hypotensive activities of Nitrendipine.	Approved
Metoprolol	Metoprolol may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Metyrosine	Nitrendipine may increase the hypotensive activities of Metyrosine.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Nitrendipine.	Experimental
Mibefradil	Nitrendipine may increase the hypotensive activities of Mibefradil.	Investigational, Withdrawn
Micafungin	The therapeutic efficacy of Micafungin can be increased when used in combination with Nitrendipine.	Approved, Investigational
Miconazole	The therapeutic efficacy of Miconazole can be increased when used in combination with Nitrendipine.	Approved, Investigational, Vet Approved
Mifepristone	The serum concentration of Nitrendipine can be increased when it is combined with Mifepristone.	Approved, Investigational
Miltefosine	The therapeutic efficacy of Miltefosine can be increased when used in combination with Nitrendipine.	Approved, Investigational
Minaprine	Minaprine may increase the hypotensive activities of Nitrendipine.	Approved
Minoxidil	Minoxidil may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Mirodenafil	Mirodenafil may increase the antihypertensive activities of Nitrendipine.	Investigational
Mitotane	The serum concentration of Nitrendipine can be decreased when it is combined with Mitotane.	Approved
Moclobemide	Moclobemide may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Moexipril	Moexipril may increase the hypotensive activities of Nitrendipine.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Monensin	The therapeutic efficacy of Monensin can be increased when used in combination with Nitrendipine.	Vet Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Nitrendipine.	Approved, Investigational
Moxonidine	Moxonidine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Muzolimine	Nitrendipine may increase the hypotensive activities of Muzolimine.	Experimental
Myxothiazol	The therapeutic efficacy of Myxothiazol can be increased when used in combination with Nitrendipine.	Experimental
Nabilone	The risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine.	Approved, Investigational
Nadolol	Nitrendipine may increase the hypotensive activities of Nadolol.	Approved
Nafcillin	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nafcillin.	Approved, Investigational
Naftifine	The therapeutic efficacy of Naftifine can be increased when used in combination with Nitrendipine.	Approved
Naftopidil	Nitrendipine may increase the hypotensive activities of Naftopidil.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Nitrendipine.	Approved
Natamycin	The therapeutic efficacy of Natamycin can be increased when used in combination with Nitrendipine.	Approved
Nebivolol	Nitrendipine may increase the hypotensive activities of Nebivolol.	Approved, Investigational
Nefazodone	The metabolism of Nitrendipine can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Nitrendipine can be decreased when combined with Nelfinavir.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nesiritide.	Approved, Investigational
Netupitant	The serum concentration of Nitrendipine can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The metabolism of Nitrendipine can be increased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the hypotensive activities of Nitrendipine.	Withdrawn
Nicardipine	Nicardipine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Nitrendipine.	Approved, Investigational
Nicorandil	Nicorandil may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Nifedipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nifedipine.	Approved
Nifuratel	The therapeutic efficacy of Nifuratel can be increased when used in combination with Nitrendipine.	Experimental
Niguldipine	Nitrendipine may increase the hypotensive activities of Niguldipine.	Experimental
Nikkomycin Z	The therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Nitrendipine.	Investigational
Nilotinib	The metabolism of Nitrendipine can be decreased when combined with Nilotinib.	Approved, Investigational
Nilvadipine	Nitrendipine may increase the hypotensive activities of Nilvadipine.	Approved, Investigational
Nimodipine	Nimodipine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Nitrendipine.	Approved
Nisoldipine	Nisoldipine may increase the hypotensive activities of Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	Nitrendipine may increase the hypotensive activities of Nitroprusside.	Approved, Investigational
Nitrous acid	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitrous acid.	Approved, Investigational
Nitroxoline	The therapeutic efficacy of Nitroxoline can be increased when used in combination with Nitrendipine.	Approved
Nortriptyline	The risk or severity of hypotension can be increased when Nortriptyline is combined with Nitrendipine.	Approved
Nystatin	The therapeutic efficacy of Nystatin can be increased when used in combination with Nitrendipine.	Approved, Vet Approved
Obinutuzumab	Nitrendipine may increase the hypotensive activities of Obinutuzumab.	Approved, Investigational
Octamoxin	Octamoxin may increase the hypotensive activities of Nitrendipine.	Withdrawn
Olanzapine	The risk or severity of hypotension can be increased when Olanzapine is combined with Nitrendipine.	Approved, Investigational
Olaparib	The metabolism of Nitrendipine can be decreased when combined with Olaparib.	Approved
Olmesartan	Olmesartan may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Omapatrilat	Omapatrilat may increase the hypotensive activities of Nitrendipine.	Investigational
Omoconazole	The therapeutic efficacy of Omoconazole can be increased when used in combination with Nitrendipine.	Experimental
Osimertinib	The serum concentration of Nitrendipine can be increased when it is combined with Osimertinib.	Approved
Oxiconazole	The therapeutic efficacy of Oxiconazole can be increased when used in combination with Nitrendipine.	Approved
Oxprenolol	Nitrendipine may increase the hypotensive activities of Oxprenolol.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Paclitaxel.	Approved, Vet Approved
Pafuramidine	The therapeutic efficacy of Pafuramidine can be increased when used in combination with Nitrendipine.	Investigational
Palbociclib	The serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.	Approved, Investigational
Paliperidone	The risk or severity of hypotension can be increased when Paliperidone is combined with Nitrendipine.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Papaverine.	Approved, Investigational
Pargyline	Pargyline may increase the hypotensive activities of Nitrendipine.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.	Approved
Penbutolol	Nitrendipine may increase the hypotensive activities of Penbutolol.	Approved, Investigational
Pentamidine	The therapeutic efficacy of Pentamidine can be increased when used in combination with Nitrendipine.	Approved, Investigational
Pentobarbital	The metabolism of Nitrendipine can be increased when combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pentolinium	Nitrendipine may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Nitrendipine.	Approved, Investigational, Vet Approved, Withdrawn
Perindopril	Perindopril may increase the hypotensive activities of Nitrendipine.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Nitrendipine.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Nitrendipine.	Withdrawn
Phenobarbital	The metabolism of Nitrendipine can be increased when combined with Phenobarbital.	Approved, Investigational
Phenoxybenzamine	Phenoxybenzamine may increase the hypotensive activities of Nitrendipine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Nitrendipine.	Withdrawn
Phentolamine	Phentolamine may increase the hypotensive activities of Nitrendipine.	Approved
Phenytoin	The metabolism of Nitrendipine can be increased when combined with Phenytoin.	Approved, Vet Approved
Pinacidil	Pinacidil may increase the hypotensive activities of Nitrendipine.	Approved
Pindolol	Pindolol may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone.	Approved, Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Nitrendipine.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine.	Approved
Pitolisant	The serum concentration of Nitrendipine can be decreased when it is combined with Pitolisant.	Approved, Investigational
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Nitrendipine.	Withdrawn
Pizotifen	The risk or severity of hypotension can be increased when Pizotifen is combined with Nitrendipine.	Approved
Platelet Activating Factor	Nitrendipine may increase the hypotensive activities of Platelet Activating Factor.	Experimental
Polythiazide	Nitrendipine may increase the hypotensive activities of Polythiazide.	Approved
Posaconazole	The metabolism of Nitrendipine can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole.	Approved, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.	Approved
Prazosin	Prazosin may increase the hypotensive activities of Nitrendipine.	Approved
Primidone	The metabolism of Nitrendipine can be increased when combined with Primidone.	Approved, Vet Approved
Procaine	Procaine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational, Vet Approved
Procarbazine	Procarbazine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Promazine	The risk or severity of hypotension can be increased when Promazine is combined with Nitrendipine.	Approved, Vet Approved
Propericiazine	The risk or severity of hypotension can be increased when Propericiazine is combined with Nitrendipine.	Approved, Investigational
Propiomazine	The risk or severity of hypotension can be increased when Propiomazine is combined with Nitrendipine.	Approved
Propiverine	The risk or severity of hypotension can be increased when Propiverine is combined with Nitrendipine.	Approved, Investigational
Propofol	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	Propranolol may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Nitrendipine.	Approved
Pyrrolnitrin	The therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Nitrendipine.	Experimental
Quetiapine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Quetiapine.	Approved
Quinapril	Quinapril may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Quinidine	The risk or severity of hypotension can be increased when Quinidine is combined with Nitrendipine.	Approved, Investigational
Quinine	Quinine may increase the hypotensive activities of Nitrendipine.	Approved
Racepinephrine	The risk or severity of hypotension can be increased when Racepinephrine is combined with Nitrendipine.	Approved
Radicicol	The therapeutic efficacy of Radicicol can be increased when used in combination with Nitrendipine.	Experimental
Ramipril	Ramipril may increase the hypotensive activities of Nitrendipine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Nitrendipine.	Approved, Investigational
Rasagiline	Rasagiline may increase the hypotensive activities of Nitrendipine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Nitrendipine.	Approved
Rescinnamine	Nitrendipine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	Reserpine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Rifabutin	The metabolism of Nitrendipine can be increased when combined with Rifabutin.	Approved, Investigational
Rifampicin	The metabolism of Nitrendipine can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Nitrendipine can be increased when combined with Rifapentine.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Nitrendipine.	Approved, Investigational
Rilmenidine	Rilmenidine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Nitrendipine.	Approved
Riociguat	Nitrendipine may increase the hypotensive activities of Riociguat.	Approved
Risperidone	Nitrendipine may increase the hypotensive activities of Risperidone.	Approved, Investigational
Rituximab	Nitrendipine may increase the hypotensive activities of Rituximab.	Approved
Ropinirole	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine.	Approved
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Nitrendipine.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine.	Approved
Rucaparib	The metabolism of Nitrendipine can be decreased when combined with Rucaparib.	Approved, Investigational
Sacubitril	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Nitrendipine.	Withdrawn
Salicylhydroxamic Acid	The therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nitrendipine.	Experimental
Salicylic acid	The therapeutic efficacy of Salicylic acid can be increased when used in combination with Nitrendipine.	Approved, Investigational, Vet Approved
Saprisartan	Nitrendipine may increase the hypotensive activities of Saprisartan.	Experimental
Saquinavir	The metabolism of Nitrendipine can be decreased when combined with Saquinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sarilumab.	Approved, Investigational
Secobarbital	The metabolism of Nitrendipine can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Nitrendipine.	Approved, Investigational, Vet Approved
Selexipag	Nitrendipine may increase the hypotensive activities of Selexipag.	Approved
Sertaconazole	The therapeutic efficacy of Sertaconazole can be increased when used in combination with Nitrendipine.	Approved, Investigational
Sevoflurane	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Nitrendipine.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Nitrendipine.	Approved
Siltuximab	The serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Nitrendipine can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Nitrendipine.	Approved
Sinefungin	The therapeutic efficacy of Sinefungin can be increased when used in combination with Nitrendipine.	Experimental
Sirolimus	The therapeutic efficacy of Sirolimus can be increased when used in combination with Nitrendipine.	Approved, Investigational
Sitaxentan	Nitrendipine may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sotalol	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sotalol.	Approved
Spirapril	Nitrendipine may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Nitrendipine can be increased when it is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase.	Approved, Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.	Approved, Investigational
Sulconazole	The therapeutic efficacy of Sulconazole can be increased when used in combination with Nitrendipine.	Approved
Sulfisoxazole	The metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Tadalafil	Tadalafil may increase the antihypertensive activities of Nitrendipine.	Approved, Investigational
Talinolol	Nitrendipine may increase the hypotensive activities of Talinolol.	Investigational
Tamsulosin	The risk or severity of hypotension can be increased when Tamsulosin is combined with Nitrendipine.	Approved, Investigational
Tavaborole	The therapeutic efficacy of Tavaborole can be increased when used in combination with Nitrendipine.	Approved, Investigational
Telaprevir	The metabolism of Nitrendipine can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The metabolism of Nitrendipine can be decreased when combined with Telithromycin.	Approved
Telmisartan	Telmisartan may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Temocapril	Nitrendipine may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Terazosin	The risk or severity of hypotension can be increased when Terazosin is combined with Nitrendipine.	Approved
Terbinafine	The therapeutic efficacy of Terbinafine can be increased when used in combination with Nitrendipine.	Approved, Investigational, Vet Approved
Terconazole	The therapeutic efficacy of Terconazole can be increased when used in combination with Nitrendipine.	Approved
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Nitrendipine.	Experimental
Terlipressin	Nitrendipine may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Tetrahydropalmatine	Nitrendipine may increase the hypotensive activities of Tetrahydropalmatine.	Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide.	Approved, Investigational, Withdrawn
Theodrenaline	Nitrendipine may increase the hypotensive activities of Theodrenaline.	Investigational
Theophylline	Theophylline may increase the antihypertensive activities of Nitrendipine.	Approved
Thiamylal	The metabolism of Nitrendipine can be increased when combined with Thiamylal.	Approved, Vet Approved
Thiopental	The metabolism of Nitrendipine can be increased when combined with Thiopental.	Approved, Vet Approved
Thioproperazine	The risk or severity of hypotension can be increased when Thioproperazine is combined with Nitrendipine.	Approved
Thioridazine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thioridazine.	Approved, Withdrawn
Thymol	The therapeutic efficacy of Thymol can be increased when used in combination with Nitrendipine.	Approved
Tibolone	Nitrendipine may increase the hypotensive activities of Tibolone.	Approved, Investigational
Ticlopidine	The metabolism of Nitrendipine can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	Nitrendipine may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	Timolol may increase the hypotensive activities of Nitrendipine.	Approved
Tioconazole	The therapeutic efficacy of Tioconazole can be increased when used in combination with Nitrendipine.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine.	Approved, Investigational
Tocilizumab	The serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Nitrendipine.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone.	Approved, Withdrawn
Tolciclate	The therapeutic efficacy of Tolciclate can be increased when used in combination with Nitrendipine.	Experimental
Tolnaftate	The therapeutic efficacy of Tolnaftate can be increased when used in combination with Nitrendipine.	Approved, Investigational, Vet Approved
Tolonidine	Nitrendipine may increase the hypotensive activities of Tolonidine.	Experimental
Toloxatone	Toloxatone may increase the hypotensive activities of Nitrendipine.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Nitrendipine.	Approved, Investigational
Torasemide	Torasemide may increase the hypotensive activities of Nitrendipine.	Approved
Trandolapril	Trandolapril may increase the hypotensive activities of Nitrendipine.	Approved
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Travoprost	Travoprost may increase the hypotensive activities of Nitrendipine.	Approved
Trazodone	The risk or severity of hypotension can be increased when Trazodone is combined with Nitrendipine.	Approved, Investigational
Treprostinil	Treprostinil may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Triamterene.	Approved
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Nitrendipine.	Approved, Vet Approved
Trifluoperazine	The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nitrendipine.	Approved, Investigational
Trimazosin	Trimazosin may increase the hypotensive activities of Nitrendipine.	Experimental
Trimethaphan	Trimethaphan may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Trimetrexate	The therapeutic efficacy of Trimetrexate can be increased when used in combination with Nitrendipine.	Approved, Investigational
Trimipramine	The risk or severity of hypotension can be increased when Trimipramine is combined with Nitrendipine.	Approved
Udenafil	Udenafil may increase the antihypertensive activities of Nitrendipine.	Approved, Investigational
Unoprostone	Nitrendipine may increase the hypotensive activities of Unoprostone.	Approved, Investigational
Urapidil	Urapidil may increase the hypotensive activities of Nitrendipine.	Investigational
Ursodeoxycholic acid	Ursodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Valsartan	Valsartan may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Nitrendipine.	Approved
Vemurafenib	The serum concentration of Nitrendipine can be decreased when it is combined with Vemurafenib.	Approved
Venlafaxine	The metabolism of Nitrendipine can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Nitrendipine can be decreased when combined with Verapamil.	Approved
Vincamine	Nitrendipine may increase the hypotensive activities of Vincamine.	Experimental
Vincristine	The excretion of Vincristine can be decreased when combined with Nitrendipine.	Approved, Investigational
Vinpocetine	Nitrendipine may increase the hypotensive activities of Vinpocetine.	Investigational
Voriconazole	The metabolism of Nitrendipine can be decreased when combined with Voriconazole.	Approved, Investigational
Wortmannin	The therapeutic efficacy of Wortmannin can be increased when used in combination with Nitrendipine.	Experimental
Xipamide	Nitrendipine may increase the hypotensive activities of Xipamide.	Experimental
Xylometazoline	Nitrendipine may increase the hypotensive activities of Xylometazoline.	Approved, Investigational
Yohimbine	Yohimbine may decrease the antihypertensive activities of Nitrendipine.	Approved, Investigational, Vet Approved
Ziprasidone	The metabolism of Nitrendipine can be decreased when combined with Ziprasidone.	Approved
Zofenopril	Nitrendipine may increase the hypotensive activities of Zofenopril.	Experimental
Zuclopenthixol	The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nitrendipine.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, "Preparation of solid medicament formulation containing nitrendipine." U.S. Patent US4724141, issued April, 1980.

US4724141

General References

Not Available

External Links

Human Metabolome Database: HMDB0015187
KEGG Drug: D00629
KEGG Compound: C07713
PubChem Compound: 4507
PubChem Substance: 46508817
ChemSpider: 4351
BindingDB: 50012016
ChEBI: 7582
ChEMBL: CHEMBL475534
Therapeutic Targets Database: DAP001263
PharmGKB: PA146096020
IUPHAR: 2334
Guide to Pharmacology: GtP Drug Page
Wikipedia: Nitrendipine

ATC Codes

C08CA08 — Nitrendipine

C09BB06 — Enalapril and nitrendipine

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Unknown Status	Treatment	High Blood Pressure (Hypertension)	1
4	Withdrawn	Treatment	Chronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	156-160 °C	Not Available
water solubility	Insoluble	Not Available
logP	2.88	MASUMATO,K ET AL. (1995)
Caco2 permeability	-4.77	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.0142 mg/mL	ALOGPS
logP	3.21	ALOGPS
logP	2.17	ChemAxon
logS	-4.4	ALOGPS
pKa (Strongest Basic)	5.43	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	110.45 Å²	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	96.91 m³·mol^-1	ChemAxon
Polarizability	36.25 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9536
Blood Brain Barrier	-	0.9549
Caco-2 permeable	+	0.7853
P-glycoprotein substrate	Substrate	0.5265
P-glycoprotein inhibitor I	Inhibitor	0.8564
P-glycoprotein inhibitor II	Inhibitor	0.8313
Renal organic cation transporter	Non-inhibitor	0.8984
CYP450 2C9 substrate	Non-substrate	0.8212
CYP450 2D6 substrate	Non-substrate	0.8931
CYP450 3A4 substrate	Substrate	0.7266
CYP450 1A2 substrate	Inhibitor	0.9107
CYP450 2C9 inhibitor	Inhibitor	0.8949
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Inhibitor	0.8993
CYP450 3A4 inhibitor	Inhibitor	0.8037
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.9247
Ames test	Non AMES toxic	0.7334
Carcinogenicity	Non-carcinogens	0.5186
Biodegradation	Not ready biodegradable	0.9581
Rat acute toxicity	2.3810 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8131
hERG inhibition (predictor II)	Non-inhibitor	0.9094

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0ab9-2539000000-3d9a9111a145f234fc24
MS/MS Spectrum - , positive	LC-MS/MS	splash10-016r-0159000000-7b0ccf9fb639868092f0
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-016r-0159000000-4e10a6643ba97ab23a0f

Taxonomy

Description: This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Pyridines and derivatives
Sub Class: Hydropyridines
Direct Parent: Dihydropyridinecarboxylic acids and derivatives
Alternative Parents: Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines
show 6 more
Substituents: Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide
show 23 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: C-nitro compound, ethyl ester, diester, dihydropyridine (CHEBI:7582)

Targets

Property	Measurement	pH	Temperature (°C)	References
Kd (nM)	0.26	N/A	N/A	2329573
Ki (nM)	0.25	N/A	N/A	2435904

Details1. Voltage-dependent L-type calcium channel subunit alpha-1C

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1C
Uniprot ID: Q13936
Uniprot Name: Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight: 248974.1 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]

Details2. Voltage-dependent calcium channel subunit alpha-2/delta-1

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name: CACNA2D1
Uniprot ID: P54289
Uniprot Name: Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight: 124566.93 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]

Details3. Voltage-dependent L-type calcium channel subunit beta-2

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name: CACNB2
Uniprot ID: Q08289
Uniprot Name: Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight: 73579.925 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]

Details4. Voltage-dependent calcium channel gamma-1 subunit

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name: CACNG1
Uniprot ID: Q06432
Uniprot Name: Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight: 25028.105 Da

References

Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]

Details5. Voltage-dependent L-type calcium channel subunit alpha-1D

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1D
Uniprot ID: Q01668
Uniprot Name: Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight: 245138.75 Da

References

Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]

Details6. Voltage-dependent L-type calcium channel subunit alpha-1S

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1S
Uniprot ID: Q13698
Uniprot Name: Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight: 212348.1 Da

References

Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]

Details7. Voltage-dependent calcium channel subunit alpha-2/delta-2

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Voltage-gated calcium channel activity
Specific Function: The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name: CACNA2D2
Uniprot ID: Q9NY47
Uniprot Name: Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight: 129816.095 Da

References

Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]

Details8. Voltage-dependent T-type calcium channel subunit alpha-1H

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Scaffold protein binding
Specific Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name: CACNA1H
Uniprot ID: O95180
Uniprot Name: Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight: 259160.2 Da

References

Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details2. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Oxygen binding
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP3A5
Uniprot ID: P20815
Uniprot Name: Cytochrome P450 3A5
Molecular Weight: 57108.065 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details3. Cytochrome P450 3A7

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Oxygen binding
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP3A7
Uniprot ID: P24462
Uniprot Name: Cytochrome P450 3A7
Molecular Weight: 57525.03 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 06:44

Nitrendipine

Identification

Structure for DB01054 (Nitrendipine)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

References

References

References

References

References

Enzymes

References

References

References

Transporters

References